BELLUSCURA PLC

Capital/Financing Update • Aug 11, 2025

National Storage Mechanism | Additional information

RNS Number : 7660U

Belluscura PLC

11 August 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

11 August 2025

Belluscura plc

("Belluscura" or the "Company")

Update re Strategic Review and Proposed Fundraising

Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, provides an update further to the announcement of 30 June 2025 detailing a Proposed Fundraising (the "Announcement").

Omaha Value, Inc ("Omaha")

Despite ongoing dialogue with Omaha since the Announcement, and notwithstanding the Company having requested from Omaha on several occasions draw down of the initial $250,000 subscribed by Omaha under the $1.5 million Loan Note, to date no funds have been received. Consequently, the Company has notified Omaha that the Loan Note is terminated in accordance with its terms.  

As a result of the termination of the Loan Note agreement, any warrants issued or to be issued in connection with the Loan Note facility are deemed invalid and cancelled with immediate effect.

Non Binding Letter of Intent to dispose of certain assets of the Company

The Company has been actively reviewing financial and strategic alternatives with the objective of achieving value for creditors, convertible loan note holders and shareholders of the Company.

The Company has signed a non-binding letter of intent with a US medical device company ("Potential Acquirer") whereby the Potential Acquirer proposes, subject to, inter alia, completion of due diligence and entering into an asset purchase agreement, to acquire certain assets and liabilities of the Company relating to its X-PLOR and DISCOV-R product offering, and/or other products, Intellectual Property, Shenzhen Belluscura Technology Company Limited, and regulatory and manufacturing registrations in US, China, Hong Kong and Singapore (the "Assets").

The Potential Acquirer has been granted a 15 day exclusivity period from 11 August 2025 to undertake due diligence on the Assets.

It is expected that the detailed terms of the proposed purchase will be agreed by the Company and the Potential Acquirer during the exclusivity period.

Disposal of the Assets will be subject to approval by shareholders at a general meeting of Company as required by AIM Rule 15 of the AIM Rules for Companies. 

The ongoing funding discussions means that the Company is not yet able to finalise the 2024 Annual Report and Accounts and as a result trading in the Company's shares remains suspended.

A further announcement will be made in due course.

Capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the "Update regarding Strategic Review and proposed Fundraising" announcement published by the Company at 7.00 a.m. on 30 June 2025.

For further information please contact:

Belluscura plc	Tel: +44 (0)20 3128 8100
Paul Tuson, Chairman Robert Rauker, Chief Executive Officer
SPARK Advisory Partners Limited Nominated Adviser Neil Baldwin	Tel: +44 (0)20 3368 3550
Dowgate Capital Limited Joint Broker Russell Cook / Daniel Ingram	Tel: +44 (0)20 3903 7715
Allenby Capital Limited Joint Broker Guy McDougall / Amrit Nahal (Sales and Corporate Broking) Jeremy Porter / Lauren Wright (Corporate Finance)	Tel: +44 (0)20 3328 5656
MHP Financial PR & Investor Relations	Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com
Katie Hunt / Matthew Taylor

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDSFIEFSEISEFA